Page last updated: 2024-10-26

dipyridamole and Niemann-Pick Disease, Type C

dipyridamole has been researched along with Niemann-Pick Disease, Type C in 1 studies

Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.

Niemann-Pick Disease, Type C: An autosomal recessive lipid storage disorder that is characterized by accumulation of CHOLESTEROL and SPHINGOMYELINS in cells of the VISCERA and the CENTRAL NERVOUS SYSTEM. Type C (or C1) and type D are allelic disorders caused by mutation of the NPC1 gene, which encodes a protein that mediates intracellular cholesterol transport from LYSOSOMES. Clinical signs include hepatosplenomegaly and chronic neurological symptoms. Type D is a variant in people with a Nova Scotia ancestry.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Pepponi, R1
De Simone, R1
De Nuccio, C1
Visentin, S1
Matteucci, A1
Bernardo, A1
Popoli, P1
Ferrante, A1

Other Studies

1 other study available for dipyridamole and Niemann-Pick Disease, Type C

ArticleYear
Repurposing Dipyridamole in Niemann Pick Type C Disease: A Proof of Concept Study.
    International journal of molecular sciences, 2022, Mar-22, Volume: 23, Issue:7

    Topics: Adenosine; Animals; Dipyridamole; Drug Repositioning; Humans; Mice; Niemann-Pick Disease, Type C; Pr

2022